14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
NVS vs MRK: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Novartis AG (NVS) is the stronger overall head-to-head candidate over Merck & Co., Inc. (MRK) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). NVS carries a Unified Composite Score of 41.5/100 (SELL) at $161.59 (16.2x Forward P/E, 34.0% operating margin), whereas MRK carries 57.1/100 (HOLD) at $146.35 (16.4x Forward P/E, 35.2% operating margin).
Composite vs. Pillar Nuance: While MRK currently prints a higher short-term Unified Composite Score (57.1/100 HOLD vs. NVS 41.5/100 SELL), NVS captures the overall institutional head-to-head verdict (5–4 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (34.0% vs. 35.2% operating margin) and revenue trajectory (+4.7% vs. +4.7% YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NVS vs MRK. Trailing 12-month operating profitability (NVS 34.0% vs MRK 35.2%) and valuation multiples (NVS 16.2x vs MRK 16.4x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Drug Manufacturers - General value chain with $302.9B market capitalization and 34.0% operating margin.
OpEx & R&D Reinvestment41.2% of Rev ($16.7B)
90D Engineering Disclosures0 Published
MRK Moat ProfileHigh-Margin Pricing Power Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $362.3B market capitalization and 35.2% operating margin.
OpEx & R&D Reinvestment40.0% of Rev ($27.0B)
90D Engineering Disclosures0 Published
Investor FAQ NVS vs MRK Key Questions & Quantitative Answers
As of Nov 16, 2026, Novartis AG (NVS) is the stronger overall head-to-head candidate over Merck & Co., Inc. (MRK) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). NVS carries a Unified Composite Score of 41.5/100 (SELL) at $161.59 (16.2x Forward P/E, 34.0% operating margin), whereas MRK carries 57.1/100 (HOLD) at $146.35 (16.4x Forward P/E, 35.2% operating margin). Composite vs. Pillar Nuance: While MRK currently prints a higher short-term Unified Composite Score (57.1/100 HOLD vs. NVS 41.5/100 SELL), NVS captures the overall institutional head-to-head verdict (5–4 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (34.0% vs. 35.2% operating margin) and revenue trajectory (+4.7% vs. +4.7% YoY).
MRK leads the Growth & Scale pillar: NVS posts +4.7% YoY revenue growth and -68.8% YoY earnings growth on $40.5B TTM revenue (75.2% gross margin, 34.0% operating margin), compared with MRK at +4.7% YoY revenue growth and -12.0% YoY earnings growth on $67.4B TTM revenue (75.2% gross margin, 35.2% operating margin). On trailing 12-month operating scale, NVS generates $40.5B in USD-normalized revenue versus $67.4B for MRK. In operating R&D and SG&A reinvestment, NVS deploys 41.2% of Rev ($16.7B) (0 90-day corporate R&D disclosures) versus 40.0% of Rev ($27.0B) (0 disclosures) for MRK.
NVS screens cheaper on headline valuation multiples. NVS trades at 16.2x Forward P/E, 30.6x Trailing P/E, 3.81x PEG, and 7.5x EV/Revenue (42.0% EBITDA margin), whereas MRK trades at 16.4x Forward P/E, 148.4x Trailing P/E, 3.56x PEG, and 6.0x EV/Revenue (21.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NVS (24.3% ROE) versus MRK (5.1% ROE) capital efficiency.
In options market volatility and institutional positioning, NVS carries 16.9% implied volatility (6th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.31β · 27% Vol realized risk). By comparison, MRK carries 110.2% implied volatility (100th %ile, Extreme (>80th %ile)), a 0.52x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.19β · 31% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.